Boehringer Ingelheim has inked a deal worth up to $509 million with biotech Phenomic AI to develop new targets in stroma-rich cancers, the companies announced Wednesday. Boehringer Ingelheim will pay $9 million immediately and up to $500 million in potential milestones.
privacy policy | terms of use | contact us | advertise | pharma blogs | facebook | twitter
Copyright © 2025,